TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics , a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long COVID, today announced two major milestones supporting the advancement of its planned SHIELD Study, a randomized, double-blind, placebo-controlled Phase 2 Long COVID clinical study. This study will be conducted in collaboration with the Icahn School of Medicine at Mount Sinai under the leade

PASADENA, Calif.--(BUSINESS WIRE)-- $arwr --Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $

– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – ALAMEDA, Calif. & AUSTIN, Texas --(BUSINESS WIRE)--Jan. 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis -sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalint

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3 -ITD positive AML MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA ® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3 -ITD positi

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 SAN CARLOS, Calif.--(BUSINESS WIRE)-- $ONC #BeOne -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from t

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ADI-001) in ongoing and future clinical studies All seven cohorts now actively enrolling in Phase 1 autoimmune clinical program as first anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) patient is dosed in study Next clinical update from Phase 1 study of prula-cel in auto

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expec

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All securities in the offerin

BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 7, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT, to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority . Pending approval, Sarepta expect